This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Align Technology, based in California, manufactures and markets a system of clear aligner therapy, intra-oral scanners and CAD/CAM (computer-aided design and computer-aided manufacturing) digital services used in dentistry, orthodontics, and dental records storage. The clear aligner system corrects malocclusion using nearly invisible and removable appliances that gently move the tooth to a desired final position.
Cerner (CERN) to Buy Kantar Health to Enhance Clinical Research
by Zacks Equity Research
Cerner (CERN) agrees to acquire Kantar Health to drive safety and efficiency of clinical research across life sciences, pharmaceuticals and health care.
Here's Why You Should Add Hologic (HOLX) to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Hologic (HOLX) on robust growth of the Diagnostics segment and regulatory approvals.
Here's Why You Should Hold onto Varian Medical (VAR) Stock Now
by Zacks Equity Research
Investor confidence is high on Varian Medical (VAR) stock, courtesy of solid prospects.
Grab 3 Dental Stocks More Than Doubling Industry Gains for 2021
by Trina Mukherjee
Buy these three top dental stocks that have shown sharp recovery despite market volatility due to the pandemic, and have the potential to continue their bull run in 2021.
Veeva (VEEV) Vault QMS Gets Picked by Samsung Biologics
by Zacks Equity Research
Veeva Systems' (VEEV) Vault Quality Suite gets selected by Samsung Biologics to drive quality process and content management for better visibility across the latter's global processes.
PDCO or ALGN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
PDCO vs. ALGN: Which Stock Is the Better Value Option?
Here's Why You Should Retain AMN Healthcare (AMN) Stock Now
by Zacks Equity Research
AMN Healthcare (AMN) continues to gain traction from its wide range of services, and Healthcare MSP. Intense competition remains a woe.
NextGen's (NXGN) HDH to Facilitate Health Information Exchange
by Zacks Equity Research
NextGen's (NXGN) HDH has been chosen by HI-BRIDGE HIE for secure sharing of patient health data from multiple sources.
Masimo (MASI) Releases Favorable Findings on Pulse Oximetry
by Zacks Equity Research
Researchers on probe discover that the use of Masimo's (MASI) SpHb was related to the lower rate of postoperative transfusion, minimal duration of ICU stay and other better outcomes.
Here's Why You Should Retain Fresenius Medical (FMS) Stock
by Zacks Equity Research
Fresenius Medical (FMS) continues to gain traction from its broad range of dialysis products and services. However, intense competition remains a woe.
Cerner's (CERN) Simplified Digital Tools to Aid Health Systems
by Zacks Equity Research
Cerner (CERN) offers centralized digital ordering and monitoring for clients in order to help health systems.
Here's Why You Should Hold on to McKesson (MCK) Stock Now
by Zacks Equity Research
McKesson (MCK) continues to benefit from multi-year strategic growth initiative and Distribution Solutions segment.
Simbec-Orion to Adopt Veeva's (VEEV) Vault Applications
by Zacks Equity Research
Veeva's (VEEV) clinical solutions will offer Simbec-Orion real-time insights into studies in phases to accelerate trial execution.
Cerner's (CERN) Deal to Make Clinical Trials More Accessible
by Zacks Equity Research
Cerner (CERN) inks deal with Elligo Health Research to make clinical trials more accessible, while minimizing costs.
Here's Why You Should Hold on to Nevro (NVRO) Stock Now
by Zacks Equity Research
Investors grew bullish on Nevro's (NVRO) prospects, courtesy of the stock's solid prospects.
HealthEquity (HQY) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
HealthEquity (HQY) delivers strong growth in Service, Custodial and Interchange segments in Q3.
Here's Why You Should Retain Change Healthcare (CHNG) Stock
by Zacks Equity Research
Change Healthcare (CHNG) continues to benefit from robust payment accuracy business and strategic deals. However, intense competition remains a woe.
NextGen (NXGN) Reinforces Its Robust Solutions Portfolio
by Zacks Equity Research
NextGen's (NXGN) solid solutions portfolio receives further boost with the success of its Population Health tool.
Veeva (VEEV) Vault Applications Get Adopted by GenesisCare
by Zacks Equity Research
Veeva Systems' (VEEV) clinical capabilities will allow GenesisCare Clinical CRO to rationalize trial procedures and expedite execution of the same.
Baxter's (BAX) Vital Edge Program Aids Patient Blood Management
by Zacks Equity Research
Baxter's (BAX) Vital Edge program enables AdventHealth Tampa to achieve cost savings.
Here's Why You Should Retain LHC Group (LHCG) Stock Now
by Zacks Equity Research
LHC Group (LHCG) continues to gain traction from its broad range of services, and strategic acquisitions and joint ventures.
Cooper Companies (COO) Q4 Earnings & Revenues Top Estimates
by Zacks Equity Research
Cooper Companies' (COO) fiscal fourth-quarter earnings reflect weak segmental performance. However, it exceeds expectation as it witnesses faster-than-anticipated recovery.
Here's Why You Should Invest in Cardinal Health (CAH) Stock
by Zacks Equity Research
Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment, diversified product portfolio and buyouts.
Why You Should Retain Pacific Biosciences (PACB) Stock Now
by Zacks Equity Research
Investor confidence is high on Pacific Biosciences (PACB) stock, courtesy of its solid prospects.
Zimmer Biomet (ZBH) Boosts Portfolio With A&E Medical Buyout
by Zacks Equity Research
This latest development aligns with Zimmer Biomet's (ZBH) active portfolio management strategy and the ongoing transformation of business aimed at long-term growth.